• Publications
  • Influence
Antitumour metal compounds: more than theme and variations.
Triggered by the resounding success of cisplatin, the past decades have seen tremendous efforts to produce clinically beneficial analogues. The recent achievement of oxaliplatin for the treatment ofExpand
  • 665
  • 8
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).
Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials.Expand
  • 702
  • 6
KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
The promising drug candidate indazolium trans‐[tetrachlorobis(1H‐indazole)ruthenate(III)] (KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review, which is an updateExpand
  • 459
  • 6
The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways
An investigation of the molecular mechanism of the anticancer activity demonstrated by the ruthenium(II)–arene compound [Ru(η6-p-cymene)Cl2(pta)] (pta is 1,3,5-triaza-7-phosphaadamantane), termedExpand
  • 185
  • 5
Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
A series of ruthenium(II)-arene (RAPTA) compounds were evaluated for their ability to inhibit thioredoxin reductase (either cytosolic or mitochondrial) and cathepsin B, two possible targets forExpand
  • 222
  • 4
A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core.
Keywords: bioinorganic chemistry ; cancer ; histone binding ; nucleosomes ; Rapta-C ; ruthenium ; Mass-Spectrometry ; Anticancer Metallodrugs ; Complexes ; Chromatin ; Binding ; Dna ; Particle ;Expand
  • 137
  • 4
High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides.
Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS) has been used to probe the interaction of the anticancer drug cisplatin with oligonucleotides. The binding kinetics, the natureExpand
  • 48
  • 4
Anticancer activity of metal complexes: involvement of redox processes.
Cells require tight regulation of the intracellular redox balance and consequently of reactive oxygen species for proper redox signaling and maintenance of metal (e.g., of iron and copper)Expand
  • 282
  • 3
Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy
Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) shows particular promise as an antitumour agent against colorectal cancer. It is known that KP1019 reacts with human serumExpand
  • 160
  • 3
  • PDF